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Abstract Nasal NK/T-cell lymphoma (NKTCL) is an
uncommon disease, but usually shows a highly aggressive
clinical course. The disease is much more frequent in Asian
and Latin American countries than in Western countries,
and is universally associated with Epstein–Barr virus
(EBV) infection. Analyses of gene mutations, especially
p53 and c-KIT, revealed the different frequencies by dis-
trict. Epidemiological studies revealed the changes of the
disease frequency in Korea during the period from 1977–
1989 to 1990–1996. Case-control study showed that the
exposure to pesticides and chemical solvents could be
causative of NKTCL. Further studies including HLA
antigen typing of patients is necessary to further clarify the
disease mechanism.
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Rapid destruction of the nose and face (midline) was ﬁrstly
described by McBride in 1897 [1]. Macroscopically the
lesions usually looked like necrotic granuloma and the
patients showed aggressive and lethal course, therefore
the term ‘‘lethal midline granuloma (LMG)’’ or ‘‘granu-
loma gangrenescens’’ were used for this condition. Later
the term LMG is popularly used. It had became evident that
the LMG is composed of three different types of histology,
i.e. Wegener’s granulomatosis (WG), polymorphic reticu-
losis (PR) or midline malignant reticulosis (MMR), and
malignant lymphoma [2, 3]. These diseases could be his-
tologically differentiated from each other by taking clinical
ﬁndings into account. WG is usually characterized by
generalized necrotizing vasculitis involving both arteries
and veins and the presence of glomerulitis [4]. Cancer and
speciﬁc inﬂammation such as tuberculosis also cause a
condition indistinguishable from LMG.
PR exhibits a polymorphous pattern of proliferation
consisting of large atypical cells with mono- or multinu-
cleus, small lymphocytes, plasma cells, benign-appearing
macrophages, neutrophils and much less frequently eosin-
ophils. PR had been considered as a variant of malignant
lymphomas because the disease is frequently disseminated
[2]. The nature of proliferating cells in PR had been con-
troversial. Once the disease was termed as nasal T-cell
lymphoma because the proliferating cells showed a posi-
tive immunoreactivity for polyclonal antibodies against T-
cells [5, 6]. However, monoclonal rerrangement of the T-
cell receptor genes was seldomly found in cases with
‘‘nasal T-cell lymphoma’’ [7]. Later Ng et al. [8] reported
that the tumor cells showed a positive immunoreactivity for
natural killer (NK) cell marker CD56. Subsequently it was
shown that proliferating cells in PR had large granular
lymphocyte morphology [9], which is a character of NK
cells or cytotoxic T-lymphocytes. There have been
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DOI 10.1007/s12185-008-0021-7accumulating evidences that PR is a neoplasm of activated
NK cells [10–13]: the proliferating cells usually show
CD2
+ , CD56
+ , CD3e
+, CD7
-, CD16
-, cytotoxic granule-
associated proteins
+ and do not exhibit rearrangement of T-
cell receptor or immunoglobulin genes (Fig. 1). Meanwhile
rearrangement of T-cell receptor genes was recorded in the
rare cases of PR [14, 15]. Although the upper respiratory
tract, especially nasal region, is the common site of pre-
sentation, NK/T-cell lymphoma of nasal type may present
in diverse extranodal sites such as gastrointestinal tract,
skin, testis, liver, and spleen [16]. In the World Health
Organization classiﬁcation, NK/T-cell lymphoma encom-
passes the lymphomas involving nasal area and nonnasal
area. Until present, there have been many review articles
on the clinical, pathological, immunohistochemical, and
immunogenetical aspects of NK/T-cell lymphomas
involving upper respiratory tract. This review focuses on
the epidemiology and molecular pathogenesis of nasal NK/
T-cell lymphoma (NLTCL).
1 Association with Epstein–Barr virus (EBV)
The association between EBV and human malignancies,
including endemic Burkitt’s lymphoma, Hodgkin lym-
phoma and non-Hodgkin’s lymphoma (NHL) of either B-
or T-immunophenotypes, has been reported. Etiological
role of EBV for development of NKTCL was ﬁrstly
reported in 1990 [17]. Subsequent study revealed the
constant association of NKTCL with EBV in the world
(Fig. 2) (Table 1)[ 18–23]. Sino-nasal lymphomas are
immunophenotypically classiﬁed into NK/T-(CD56
+), T-,
and B-cell type with distinctive clinical features [24].
CD56 positivity, therefore NKTCL, was closely associated
with EBV positivity among sino-nasal lymphomas [22].
EBV could be subtyped based on the difference in
sequence of EBNA2 region, i.e. type A and type B [25].
Almost all of the NKTCL in Korea and Japan had type A
Fig. 1 HE. Polymorphous
pattern of proliferation in the
nasal cavity. Large cells show
positive immunoreactivity with
CD3e, TIA-1, and CD56. ABC
method, 9400
Fig. 2 In situ hybridization with EBER-1 probe reveals positive
signals in the nucleus of proliferating cell
Table 1 EBV in nasal NK/T-cell lymphoma
Source Country EBV positive
rate (%)
EBV subtype Expression
of latent
[18]
a France 7/7 (100) NA 7/7 LMP+
[20] China 21/21 (100) NA 5/21 LMP-1+
[21] Japan 11/12 (92) 10/11 typeA 8/12 LMP-1+
[22] Korea 15/16 (94) 15/15 typeA 7/15 LMP-1+
[24] Indonesia 18/20 (90) NA NA
EBV Epstein–Barr virus, LMP latent membrane protein, NA not
available
a Fresh tissue samples were used in the analyses
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123EBV, which is identical with the previous literature
reporting that most cases of EBV-associated malignancies
of immunocompetent patients in Asia had type A EBV
[26]. Predominance of type A EBV was also found in
NKTCL in Malaysia [27], indicating the predominance of
type A EBV in NKTCL in Asia. Several studies indicated
the occurrence of type B EBV in lymphoma of immuno-
compromised patients [28]. Borisch et al. [29] reported that
three of six cases of NKTCL in Switzerland had type B
EBV, although no ﬁndings suggestive of immunodeﬁ-
ciency were found in these patients. These ﬁndings suggest
a geographic difference in the distribution of EBV subtype
in the NKTCL.
As shown in Table 1, the proliferating cells in NKTCL
frequently express latent membrane protein (LMP) as
revealed by immunohistochemistry. Latent infection gene
products of EBV, EBNA-2 and LMP-1, serve as target
antigens for the elimination of EBV infected cells by host
cytotoxic T-lymphocytes (CTL) [30]. Shen et al. [31]
showed that NKTCL cells are able to provide target epi-
topes of EBV for CTL. In immunocompromised hosts,
proliferating cells expressing EBNA-2 and LMP-1 can
escape from immune surveillance by the host CTL, which
might result in the development of malignant lymphomas
[32]. However, systemic immunosuppression is not noted
in patients with NKTCL, thus suggesting an unknown
underlying mechanism for escape of LMP-1-expressing
tumor cells from the CTL. Several mechanisms such as
downregulation of the immunogenic EBV nuclear antigens
and preferential selection of the deletion genotype of LMP-
1 was reported by Chiang et al. [33, 34] and expression of
IL-10, an immunosuppressive cytokine, was reported by
Shen et al. [31]. The cells expressing viral antigens are
eliminated primarily by CTL in a MHC-class-I-restricted
manner [35]. Two CTL-epitopes were identiﬁed in LMP-1
that are possibly pan A*02-restricted [36]. It is possible
that NKTCL patients show lower frequencies of A*02
allele compared with those in the normal population.
Indeed high-resolution genetic typing revealed signiﬁcantly
lower frequency of HLA-A*0201 in NKTCL than in
normal population [37]. These ﬁndings suggest that HLA-
A*0201-restricted CTL responses may function in vivo to
suppress the development of NKTCL, or in other words,
role of EBV for NKTCL development.
2 Genetical changes
Lymphoma arises from clonal expansion of lymphoid cells
that are transformed by the accumulation of genetic lesions
affecting oncogenes and tumor suppressor genes. In gen-
eral, amount of samples from NKTCL lesions available for
genetical analyses is small, and samples usually contain
massive necrotic areas. Therefore information for genetical
changes in NKTCL has been relatively limited until
present.
2.1 Alterations of tumor suppressor genes
and oncogenes
Polymerase chain reaction (PCR)—single strand confor-
mation polymorphism (SSCP) followed by direct sequence
method was employed for analyses of gene alterations in
NKTCL. The genes analyzed by this method were p53, k-
ras, c-kit, and b-catenin on the NKTCL cases from Asian
countries [38–42] and Mexico [43]. p53 is a well-known
tumor suppressor gene that causes cells with damaged
DNA to arrest at the G1 phase of cell cycle or stimulating
expression of the BAX gene, the protein that promotes
apoptosis [44]. In a wide variety of human cancers, p53
gene mutations have been detected mainly in exon 5
through 8 [45]. K-RAS, c-KIT, and b-catenin genes are
oncogenes. Greenblatt et al. [46] identiﬁed 50 studies in
which sequencing of the entire coding region of p53 had
been reported. Of the 560 mutations reported in those
papers, 87% were found in exons 5–8, and most of the
others were in exon 4 (8%). In the studies for NKTCL in
Asia, exons 4–8 or exons 5–8 were examined in one
institute (Table 2). The frequency of p53 mutations was
Table 2 p53 mutations in nasal
NK/T-cell lymphoma
Number
of cases
Exons
examined
Frequency
of mutations (%)
Predominance of
transition
mutation
Asia
Japan [41] 58 4–8 62% yes
Korea [41] 42 4–8 31% yes
China
Beijing, Chengdu [38] 42 5–8 48% yes
Shenyang [40] 20 4–8 40% yes
Indonesia [42] 27 4–8 63% yes
Mexico [43] 21 5–8 24% no
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123various by district: high in Japan and Indonesia and low in
Mexico, Korea, and Shenyang. Shenyang situates at north
China, which is adjacent to the Korean peninsula, sug-
gesting that environmental and genetical factors might
generate the differences in frequency. Transitions (G:C to
A:T) were the predominant pattern of mutations except for
Mexico, in which number of cases with mutations was only
ﬁve [43], thus the data from Mexico seemed to be not
conclusive. Predominance of transition mutations suggests
that some ‘‘endogenous’’ mutagens act in lymphomagene-
sis. The transition pattern of p53 mutations is known to be
more susceptible to spontaneous genetic instability than
transversion. While genetic instability as revealed by
widespread microsatellite instability was not found in the
cases with NKTCL [47].
Quintanilla-Martinez et al. reported the association of
p53 overexpression with poor prognosis, and p53 mutations
with large cell morphology and advanced stage [43, 48].
However these ﬁndings were not conﬁrmed by other
studies. [15, 38]
The c-KIT proto-oncogene encodes a receptor tyrosine
kinase, which is involved in normal hematopoiesis,
gametogenesis, and melanogenesis via the c-kit receptor-
ligand system. [49]. Because the development of acute
leukemia or malignant lymphoma was reported in trans-
genic mice expressing KIT [8, 14, 50], NKTCL in Asian
countries was examined for the c-kit gene mutations [41].
Frequency of c-kit mutations was signiﬁcantly higher in
China (Beijing, Chengdu) (10 of 14 cases: 71.4%) [39]
than in Japan (9 of 58 cases: 15.5%) [41], Korea (5 of 42
cases:11.9%) [41], northeast China (Shenyang) (2 of 20
cases:10%) [40], and Indonesia (3 of 27 cases :11.1%) [42].
These ﬁndings suggest that location-speciﬁc differences in
etiological factors cause speciﬁc mutations in c-kit gene.
2.2 FAS Gene Mutations
Fas (Apo-1/CD95) is a 45 kDa membrane protein
belonging to the tumor necrosis factor receptor family, and
mediates programmed cell death (apoptosis) through
binding of FAS ligand (Fas L) [51]. Fas consists of 325
amino acids with a single transmembrane domain, includ-
ing signal peptide. The 80-amino acid portion in the
cytoplasm, designated as a death signaling domain, is
essential for the apoptotic signal transduction. FAS gene
mutations were reported in about 10% cases with sporadic
non-Hodgkin’s lymphoma [52]. NKTCL frequently co-
express FAS and FAS ligand (Fas L), but the tumor cells
seldom undergo apoptosis. Some mechanisms for resis-
tance to FAS/FAS L - induced apoptosis might work in the
development of NKTCL, thus FAS gene mutations could
be one of the mechanisms. Two reports support this notion:
NKTCL cells in 9 of 15 (60%) cases [53] and 7 of 14
(50%) cases [54] showed mutations of FAS gene. Mouse T-
cell lymphoma cells transfected with mutated FAS genes
were resistant to apoptosis (Fig. 3, Fig. 4)[ 54], indicating
the mutations to be loss of function mutation. These ﬁnd-
ings suggest that accumulation of lymphoid cells with FAS
mutations provides a basis for the development of NKTCL.
Fig. 3 Summary of the FAS gene mutations found in patients with
nasal NKTCL. The shaded rectangles at the COOH-terminus of the
protein represents the small peptide added because of the frameshift
in the gene encoding FAS.TM: transmembrane domain
Fig. 4 The mouse WR19L cell line expressing recombinant human
FAS protein with (T1102C, A978G, 1095 ins A) or without (wild
type) mutations were incubated with various concentrations of anti-
FAS antibody at 37.0C for 16 h. Clones expressing FAS receptor
with any mutations (A978G, 1095 ins A, T1102C) were resistant to
apoptosis induced by the anti-FAS antibody
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Various cytogenetic alterations have been reported, of
which deletions of 6q are the common [55].
3 Epidemiological features
It had been reported that NKTCL seemed to be relatively
common among non-Hodgkin’s lymphoma in Hong Kong
[56–58]: malignant lymphomas affecting nose and naso-
pharyngeal region constituted 7.2% of extranodal
lymphomas [56] and 45 of 70 cases with malignant lym-
phomas in the nose, nasopharynx, and larynx had PR
morphology [57]. This disease is occasionally encountered
in the hospitals in Japan [5, 59, 60]. When one of the
authors (KA) visited the USA in 1987, he noticed that the
disease was quite rare in the USA, but they had consul-
tation cases from Peru. Because Japanese and a part of
Peruvian belong to Mongolian ethnic group, it was pos-
tulated that the Mongolian group might be much more
frequently affected by this disease. Then they started to
examine the frequency of NKTCL in Japan, Korea
(Seoul), and China (Shanghai) during the period from
1987 to 1993. The results are summarized in Table 3 [61–
63], in which the frequency of each disease constituting
LMG is shown as the frequency per 100,000 patients who
visited the Ear–Nose–Throat (ENT) clinic in 37 university
hospitals in Japan, Ryukyu University Hospital in Oki-
nawa, Japan, Yonsei University Hospital in Seoul, and
Shanghai Medical University Hospital. All of the histo-
logical sections were reviewed by one of the authors (KA).
Frequency of PR ranged from 8 to 40.8. That in the
Institute of Laryngology and Otology, London (1966–
1987) was four, showing two to ten times higher fre-
quencies of the PR in the east Asian countries [61]. The
disease is rare in the USA [64] and Europe [65]. The
patients with NKTCL seem to be clustered also in Latin
American countries and Indonesia [66, 67]. Information
from other parts of the world such as Africa, the Middle
and Near East, and Rusia is helpful to elucidate the eti-
ology of this disease.
At the late 1990s, otorhinolaryngologists in both Korea
and Japan had the impression that the frequency of PR
appeared to be decreasing. Then the changes in frequency
of PR with time among cases from Seoul and 59 university
hospitals in Japan were examined [68]: the frequency rate
of PR per 100,000 outpatients of ENT clinics in Seoul
decreased from 40 to 20 between the periods of 1977–1989
and 1990–1996. However, there were no signiﬁcant chan-
ges in Japan during the period studies.
3.1 Life-style and environmental factors
Epidemiological studies have revealed that the NKTCL
occurs much more frequently in Asian countries than in
Western countries and it is closely associated with EBV
infection. There are differences in frequencies of p53 and
c-kit gene mutations among patients with NKTCL in Japan,
China, and Korea. Recently the ﬁrst case of familial
NKTCL affecting a father and one of his six children was
reported [69]. They used large amounts of pesticide in a
green house. An increase in the risk of developing NHL
among individuals exposed to pesticides was reported [70,
71]. In addition, a correlation of exposure to certain pes-
ticides and organochlorines with increased titers of
antibodies to EBV was reported [72]. All these ﬁndings
might suggest a causative role for some genetical, envi-
ronmental and life style factors in the development of
NKTCL. Therefore, the epidemiological study to elucidate
whether socioenvironmental ambient factors contribute to
the development of NKTCL was conducted as a collabo-
rative study of Japan, Korea and China (Table 4)[ 73]. The
odd ratio (OR) of NKTCL was 4.15 (95% conﬁdence
interval (CI), 1.74–9.37) for farmers, 2.81 (CI 1.49–5.29)
for producers of crops, and 4.01 (CI 1.99–8.09) for pesti-
cide users. The ORs for crop producers, who minimized
their exposure to pesticides by using gloves and glasses,
and sprinkling downwind at the time of pesticide use, were
3.30 (CI 1.28–8.54), 1.18 (CI 0.11–12.13), and 2.20 (CI
0.88–5.53), respectively, which were lower than those for
producers who did not take these precautions. Exposures to
pesticides and chemical solvents could be causative factors
Table 3 Frequency of lethal
midline granuloma in Japan,
Korea (Seoul), and China
(Shanghai)
Disease Number of patients (frequency per 100,000 ENT patients)
Japan other than
Okinawa (1965–1986)
Okinawa
(1973–1991)
Seoul
(1979–1989)
Shanghai
(1979–1990)
Wegener’s granulomatosis 64(4) 1(3) 0(0) 1(4)
Polymorphic reticulosis 114(8) 9(27.4) 56(40.8) 73(9.8)
Malignant lymphoma 82(6) 11(33.5) 15(10.9) 54(7.2)
Others 42(3) 1(3) 6(4.4) 0(0)
Total 302(21) 22(69.9) 77(56) 128(17)
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123for NKTCL. Previous studies showed the increased risk of
NHL in individuals using pesticides, especially phenoxy-
acetic acid-type herbicides [74]. Association of pesticides
with risk of developing t(14;18) positive-NHL, but not
t(14;18) negative-NHL, was reported [75].
4 Conclusions
Clinical course of patients with NKTCL is usually highly
aggressive. Therefore clariﬁcation of risk factors for dis-
ease development is especially important to establish a
strategy for disease prevention. Because EBV infection and
pesticides could be risk factors for NKTCL, investigation
on effects of pesticides for EBV activation is needed.
Employment of the similar kind of the epidemiological
study is desirable in other areas than East Asia. Patients
with NKTCL cluster in Asia and Latin American countries,
therefore some genetical factors might be involved in the
disease development. Further studies including HLA anti-
gen typing of patients is important to further clarify the
mechanism for disease development.
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